Symposium of Clinical Oncology Miami Beach, FL / September 25-27, 2026

TAMP-Mediated Gemcitabine Lowers Systemic Exposure vs IV Delivery in Locally Advanced Pancreatic Cancer

September 2, 2026

A pharmacokinetic sub-study of the phase 3 TIGeR-PaC trial shows TAMP-delivered gemcitabine significantly lowers systemic exposure compared to standard IV delivery in locally advanced pancreatic cancer.

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

August 12, 2026

RenovoRx today announced its financial results for the second quarter ended June 30, 2026, and provided shareholders with a business update highlighting continued commercial momentum and clinical progress.

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

August 11, 2026

RenovoRx is pleased to announce completion of enrollment in the Company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC).

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

August 6, 2026

RenovoRx today announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock (“CARTI”).

Symposium of Clinical Oncology Miami Beach, FL / September 25-27, 2026

Recent News

TAMP-Mediated Gemcitabine Lowers Systemic Exposure vs IV Delivery in Locally Advanced Pancreatic Cancer

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors